Immutep Limited (IMMP): Price and Financial Metrics

Immutep Limited (IMMP): $2.00

0.07 (+3.63%)

POWR Rating

Component Grades













Add IMMP to Watchlist
Sign Up

Industry: Biotech



in industry


  • IMMP scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.96% of US stocks.
  • IMMP's strongest trending metric is Value; it's been moving up over the last 177 days.
  • IMMP ranks lowest in Momentum; there it ranks in the 5th percentile.

IMMP Stock Summary

  • With a price/sales ratio of 38.84, IMMUTEP LTD has a higher such ratio than 95.78% of stocks in our set.
  • With a year-over-year growth in debt of -83.28%, IMMUTEP LTD's debt growth rate surpasses just 2.22% of about US stocks.
  • As for revenue growth, note that IMMP's revenue has grown -64.26% over the past 12 months; that beats the revenue growth of just 2.82% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IMMUTEP LTD are OPT, ZYME, GOVX, IVA, and HIMX.
  • IMMP's SEC filings can be seen here. And to visit IMMUTEP LTD's official web site, go to

IMMP Stock Price Chart Interactive Chart >

Price chart for IMMP

IMMP Price/Volume Stats

Current price $2.00 52-week high $3.45
Prev. close $1.93 52-week low $1.47
Day low $1.95 Volume 54,200
Day high $2.02 Avg. volume 92,533
50-day MA $2.04 Dividend yield N/A
200-day MA $2.12 Market Cap 175.86M

Immutep Limited (IMMP) Company Bio

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha' or ‘efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

IMMP Latest News Stream

Event/Time News Detail
Loading, please wait...

IMMP Latest Social Stream

Loading social stream, please wait...

View Full IMMP Social Stream

Latest IMMP News From Around the Web

Below are the latest news stories about IMMUTEP LTD that investors may wish to consider to help them evaluate IMMP as an investment opportunity.

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial. TACTI-003 is evaluating Immutep’s first-in-class soluble LAG-3 protein eftilagimod alpha (“efti”), in combination with MSD’s (Merck & Co., I

Yahoo | January 4, 2023

The past year for Immutep (ASX:IMM) investors has not been profitable

Immutep Limited ( ASX:IMM ) shareholders should be happy to see the share price up 12% in the last quarter. But that is...

Yahoo | December 30, 2022

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population expanded to include patients with triple-negative breast cancerLate-stage clinical development efforts remain focused on frontline non-small cell lung cancer (NSCLC) in combination with anti-PD-1 therapyImmutep’s cash runway extended to the end of the 1st half of calendar year 2024 SYDNEY, AUSTRALIA, Dec.

Yahoo | December 23, 2022

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha (“efti” or “IMP321”), a first-in-clas

Yahoo | December 8, 2022

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune DiseasesMedia Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary prec

Yahoo | December 6, 2022

Read More 'IMMP' Stories Here

IMMP Price Returns

1-mo 14.29%
3-mo 8.11%
6-mo -11.50%
1-year -20.00%
3-year -16.67%
5-year 9.89%
YTD 14.29%
2022 -46.65%
2021 4.46%
2020 75.42%
2019 -2.72%
2018 17.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6656 seconds.